Insider Selling: DexCom, Inc. (DXCM) Director Sells $118,980.00 in Stock
DexCom, Inc. (NASDAQ:DXCM) Director Mark G. Foletta sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $118.98, for a total value of $118,980.00. Following the completion of the transaction, the director now directly owns 4,052 shares of the company’s stock, valued at approximately $482,106.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of DXCM opened at $114.29 on Friday. DexCom, Inc. has a 1 year low of $72.04 and a 1 year high of $156.16. The company has a quick ratio of 7.32, a current ratio of 7.64 and a debt-to-equity ratio of 1.52. The company has a market capitalization of $10.29 billion, a PE ratio of 380.97 and a beta of 0.75.
DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 21st. The medical device company reported $0.54 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.38. DexCom had a positive return on equity of 4.98% and a negative net margin of 12.32%. The business had revenue of $338.00 million during the quarter, compared to analysts’ expectations of $331.60 million. During the same period in the prior year, the firm posted $0.10 EPS. DexCom’s quarterly revenue was up 52.9% compared to the same quarter last year. As a group, equities research analysts expect that DexCom, Inc. will post 0.46 earnings per share for the current year.
DXCM has been the subject of several recent research reports. Cowen upped their price target on DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a report on Friday, February 22nd. Morgan Stanley upped their price target on DexCom from $135.00 to $160.00 and gave the company an “equal weight” rating in a report on Monday, February 25th. Canaccord Genuity upped their price target on DexCom from $140.00 to $160.00 and gave the company a “buy” rating in a report on Friday, February 22nd. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a report on Friday, December 28th. Finally, Piper Jaffray Companies upped their price target on DexCom to $165.00 and gave the company an “overweight” rating in a report on Wednesday, January 9th. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $149.53.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: DexCom, Inc. (DXCM) Director Sells $118,980.00 in Stock” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://theolympiareport.com/2019/04/20/insider-selling-dexcom-inc-dxcm-director-sells-118980-00-in-stock.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Further Reading: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.